<?xml version='1.0' encoding='utf-8'?>
<document id="30439459"><sentence text="Enabling an HCV Treatment Revolution and the Frontiers of Solid Solution Formulation." /><sentence text="The discovery and development of small molecule direct acting antiviral (DAA) drugs has revolutionized the treatment of Hepatitis C virus infection" /><sentence text=" Formulations based on solid solution technology have enabled the oral absorption of the majority of commercial DAA products starting with the approval of telaprevir in 2011"><entity charOffset="155-165" id="DDI-PubMed.30439459.s3.e0" text="telaprevir" /></sentence><sentence text=" A particularly important class of DAA drugs are those targeting nonstructural protein 5A" /><sentence text=" In addition to simply promoting the oral absorption of nonstructural protein 5A compounds, solid solutions have been used within this class of compounds to mitigate changes in absorption caused by variations in food and stomach pH" /><sentence text=" This commentary reviews the formulation and biopharmaceutical aspects of the solid solutions used to enable the recent revolution in Hepatitis C virus infection treatment" /><sentence text="" /></document>